About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

It has been about a month since the last earnings report for Corcept Therapeutics (CORT) . Shares have lost about 5.3% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Corcept due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.How Have Estimates Been Moving Since The ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Corcept Therapeutics (CORT) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.Corcept Therapeutics is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to w ...

Shares of Corcept Therapeutics Incorporated (CORT) have rallied 56.4% in the past six months against the industry’s decline of 10.5%.The company’s sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism, has been performing well. The drug has been witnessing strong demand in recent quarters and the trend is likely to continue in 2025.The company’s top line solely comprises product sales from Korlym. Sales of the drug increased almost 40% ye ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated regarding potential securities fraud or unlawful business practices [1] - A lawsuit has been filed against Corcept by a group of health insurers, alleging manipulation of the patent process to hinder Teva Pharmaceutical's generic product launch of Korlym [2] - Following the news of the lawsuit, Corcept's stock price experienced a significant decline of $8.44 per share, or 11.48%, closing at $65.09 per share [3] Company Overview - Corcept Therapeutics is known for its product Korlym, which has been a best-seller in its category [2] - The company is facing legal challenges that may impact its market position and stock performance [2][3] Legal Context - The lawsuit against Corcept highlights ongoing tensions in the pharmaceutical industry regarding patent enforcement and competition from generic drugs [2] - Pomerantz LLP, a prominent firm in corporate and securities litigation, is leading the investigation into Corcept's practices [1][4]

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth S ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are t ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Corcept Therapeutics (CORT) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Corcept Therapeutics is a member of our Medical group, which includes 1009 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring t ...

Corcept Therapeutics Incorporated (CORT) reported fourth-quarter 2024 earnings of 26 cents per share, which missed the Zacks Consensus Estimate of 37 cents. The company had reported earnings of 28 cents per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.Revenues in the fourth quarter increased 34.3% year over year to $181.9 million. However, the figure missed the Zacks Consensus Estimate of $196 million. The top line solely comprises product sales of the Cu ...

Corcept Therapeutics (CORT) Q4 2024 Earnings Call February 27, 2025 03:37 AM ET Company Participants Atabak Mokari - Chief Financial OfficerCharles Robbins - Chief Business OfficerJoseph Belanoff - Chief Executive Officer, President and DirectorWilliam Guyer - Chief Development OfficerSean Maduck - President of Endocrinology Conference Call Participants David Amsellem - Sr. Research AnalystRamakanth Swayampakula - Managing Director & Senior Research AnalystAsim Rana - Equity Analyst Operator Thank you for s ...